Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2020

View Archived Issues

Epigenetic therapy disrupts premetastatic microenvironment

FDA clears IND application for AIM-001

First patient dosed in phase I study of HLX-55

Nascent Biotech to evaluate the potential of pritumumab as therapy for COVID-19

Phase III data reported from ESCAPE-NA1 study of nerinetide

FGL1 as a novel therapeutic target in obesity

Forma Therapeutics patents HDAC6 inhibitors

Gudui Biopharma Technology identifies new compounds for stroke

Merck & Co. divulges new IDO1 inhibitors

Caloric restriction prevents negative aging effects in rats

Lead Discovery Center synthesizes HER2 and EGFR inhibitors

Target Biopharmaceutical Technology Shenzhen discloses SN-38 derivatives

SMARCA4 expression is lost in sinonasal teratocarcinosarcoma

miR-10a-5p found to be a therapeutic target for treating NSCLC

Bayer initiates phase II study of BAY-2586116 in obstructive sleep apnea

Takeda begins development of anti-SARS-CoV-2 polyclonal H-IG

New phase I trial studies imaging agent I-124 M5A to detect liver metastases from colorectal cancer

Identification of orally available PI3Kdelta inhibitors unveils Vps34 as a key selectivity target

PTP1B has a key role in memory impairment and neurodegeneration in a mouse model of familial AD

ZEB1 is associated with poorer survival in peritoneal malignant mesothelioma

EpiVax collaborates with University of Georgia and Generex to develop COVID-19 vaccines

Genentech opening enrollment in phase I study of XmAb-24306 for advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...